Stock Market Nation desk

Food & Health

Food, healthcare, biotechnology, wellness, and consumer health markets.

14 stories

Analysis

Juvmo Approval Activates AbbVie's $5B Parkinson's Plan

FDA approves Juvmo, unlocking AbbVie's projected $5B revenue path; significant impact on valuation and sector dynamics anticipated.

Food & Health

Roche's Enicepatide Boosts Competitiveness

Roche's Enicepatide triumphs in trials, affecting deal terms and valuations against GLP-1 leaders.

Sep 223 min read

Food & Health

Pfizer's Legal Tactics in $2B Vaccine Dispute

Sep 143 min read

Food & Health

Pipeline Pressures Challenge Novartis Post Avidity Deal

Sep 83 min read

Food & Health

Ionis Gains FDA Nod on Zanvastro for Rare Disease

Sep 44 min read

Food & Health

Nestlé's $393M Boost Targets Brazil Formula

Sep 33 min read

Latest Food & Health

Food & Health

Tyson's Plant Sales Invite Global Buyers, Risk Looms

Tyson's plant sales invite global offers, countering USDA, affecting deal terms and valuation in beef sector.

Sep 24 min read

Food & Health

Novartis Halts CAR-T Trials Amid Fatal Risks

Explore the valuation impact after Novartis paused CAR-T trials due to patient deaths. Sector-wide safety concerns rise.

Sep 13 min read

Food & Health

Trump's 90-Day Beef Tariff Lift: Implications for JBS

Explore deal terms and sector implications as JBS gains from Trump's tariff rollback, impacting U.S. beef market competition.

Sep 13 min read

Food & Health

Imaavy's FDA Approval: Pharma Valuation Impact

J&J's Imaavy gets FDA nod for wAIHA, reshaping deal terms and revenue paths in rare-disease pharma.

Aug 253 min read

Food & Health

Regenxbio Shares Plunge Amid Clinical Hold Setback

RGX-121 trial halt impacts Regenxbio's valuation, highlighting sector risks with spinal nodules discovery.

Aug 243 min read

Food & Health

$245M Verdict Deals Guardant Financial Blow

Patent ruling forces costly royalties on Guardant, affecting its market growth and revenue projections significantly.

Aug 243 min read

Food & Health

Pasatru Gets FDA OK, Boosts Regeneron by 4%

Regeneron climbs 4% with Pasatru's FDA nod, enhancing its foothold in orphan-drug market with premium pricing potential.

Aug 203 min read

Food & Health

JBS Pursues Pilgrim's Pride Minority Buyout

Explore JBS's offer for remaining Pilgrim's Pride shares, focusing on deal terms and valuation impact on investors.

Aug 193 min read